Deferasirox in mucormycosis: Hopefully, not defeated

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 3, 2012, Pages 783-784

  Soman, Rajeev ^a   Gupta, Neha ^a   Shetty, Anjali ^a   Rodrigues, Camilla ^a  

^a P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

Adjuvant therapy; Antifungals; Diabetes mellitus; Fungal infections

Indexed keywords

DEFERASIROX;

ADJUVANT THERAPY; DEBRIDEMENT; DIABETES MELLITUS; GASTROINTESTINAL HEMORRHAGE; HUMAN; INSECT BITE; KIDNEY DYSFUNCTION; LETTER; LIVER DYSFUNCTION; MORTALITY; MUCORMYCOSIS; RISK ASSESSMENT; TREATMENT OUTCOME;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; BENZOIC ACIDS; FEMALE; HUMANS; IRON CHELATING AGENTS; MALE; MUCORMYCOSIS; TRIAZOLES;

EID: 84856957070     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkr529     Document Type: Letter

References (3)

1. Spellberg B, Ibrahim AS, Chin-Hong PV et al. The Deferasirox-AmBisome Therapy for Mucormycosis (DEFEAT Mucor) study: a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012; 67: 715-22.
2. Reed C, Ibrahim A, Edwards JE Jr et al. Deferasirox, an iron-chelating agent, as salvage therapy for rhinocerebral mucormycosis. Antimicrob Agents Chemother 2006; 50: 3968-9.
3. Spellberg B, Andes D, Perez M et al. Safety and outcomes of open-label deferasirox iron chelation therapy for mucormycosis. Antimicrob Agents Chemother 2009; 53: 3122-5.